DSSG Group: Head & Neck

Patients with confirmed recurrent or metatastic HNSCC, with primary locations in the oral cavity, hypopharynx, larynx or oropharynx.

The purpose of this study is to evaluate the safety and efficacy of the use of a drug called ficerafusp alfa (BCA101) in combination with the immunotherapy drug pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).